YON E Health has raised €250,000 in pre-seed funding to develop a device that measures vaginal pH and temperature for tracking fertility, infection risk, and reproductive health. The round was led by PMK-Group.
The Netherlands-based company is developing an at-home device that measures vaginal pH and basal body temperature simultaneously. The technology aims to provide real-time data on menstrual cycle patterns, microbiome health, and fertility windows.
“When I started YON E, I was told vaginal health was too taboo, too complex, and too ‘niche’ for innovation and investment. That’s what motivated and pushed me even more,” said Roswitha Verwer, Founder and CEO. “For too long, women have had to guess, self-diagnose, or wait until they show symptoms and something goes wrong with their health. We’re changing that, turning silence into data women can actually use.”
The funding will support preparations for medical trials, a step toward bringing the device into clinical and consumer use.
Vaginal pH is an indicator of reproductive and gynecological health. Imbalances can signal infection risk, including bacterial vaginosis or yeast infections, as well as hormonal shifts. Current at-home pH measurement relies on single-use paper strip tests, typically used only after symptoms appear.
“Vaginal health isn’t a luxury; it’s a foundation of overall wellbeing,” said Dr. Muskaan Bhan, Chief Clinical Officer at YON E Health. “Our technology bridges the gap between research and reality, empowering women globally with real-time, clinical-grade insights that can prevent complications before they start.”
PMK-Group is led by Dr. Peter M. Kovacs, who has a PhD in gynecology. Kovacs has built a private clinical research ecosystem in Eastern Europe focused on women’s health.
“YON E Health is addressing an area that’s both underserved and scientifically critical,” said Dr. Kovacs. “Their approach, combining biosensor technology, clinical expertise, and user empathy, represents the future of proactive care in women’s health.”
